Capricor Therapeutics Announces 24-Month HOPE-3 Data On Deramiocel In Duchenne Muscular Dystrophy To Be Presented At World Muscle Society Congress September 29 To October 3

Capricor Therapeutics shares are trading higher after the company announced it will present 24-month Phase 3 HOPE-3 data for its Duchenne muscular dystrophy drug, Deramiocel, following a major BLA amendment submitted to the FDA ahead of its November 22 PDUFA date.

Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Kahn Swick & Foti, LLC announces a class action securities lawsuit against Capricor Therapeutics for failing to disclose material information regarding changes to its statistical analysis plan for its lead drug candidate Deramiocel. The FDA found the company made undisclosed modifications to the analysis plan just before data unblinding, which the agency deemed post-hoc and exploratory. Following FDA briefing documents on July 27, 2026, Capricor's stock plummeted 64% to $7.00 per share. Investors who purchased shares between December 17, 2025 and July 26, 2026 can apply to join the lawsuit by September 28, 2026.

Kirby McInerney LLP Alerts Investors Who Acquired Bloom Energy Corporation BE Securities Between February 27, 2025 and July 8, 2026 of Pending Lawsuit

Law firm Kirby McInerney LLP announced pending securities class action lawsuits against Bloom Energy Corporation for allegedly making false statements about its reliance on Chinese scandium supplies. A short-seller report on July 8, 2026 revealed that Bloom Energy sourced scandium from China through intermediaries despite claiming minimal China supply chain dependence, causing the stock to fall 5.7%. The firm is seeking lead plaintiffs with a September 28, 2026 deadline.